Clinical Trial Update: Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 study comparing RGB-14-P to Prolia in postmenopausal osteoporosis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Prolia (denosumab)
• RGB-14-P

Snippet

Sponsor: Gedeon Richter Plc. | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2024-10-24